Clinical Endocrinology Update 2019: Seattle

Seattle, WA US
September 19, 2019 to September 21, 2019

Clinical Endocrinology Update (CEU) is your opportunity to stay up-to-date on the newest breakthroughs in clinical endocrinology. Expert faculty deliver a comprehensive three-day program covering a range of clinical practice areas using interactive, case-based learning. 

Click the start button to:

  1. Complete a brief meeting evaluation
  2. Enter the credit total commensurate with CEU 2019 accredited session attendance
  3. View/Download/Print Certificate

In compliance with Accreditation Council for Continuing Medical Education policy and procedures, the Endocrine Society will be unable to accept MOC credit submissions after December 31, 2019.  Please plan to claim your credits accordingly.

If you also attended the Endocrine Board Review course claim your CME and MOC!

Additional CME and MOC

If you attended any of the lunch events claim your credit below:

Growth Hormone Deficiency: Thursday Sept. 19

Thyroid Eye Disease: Friday Sept. 20

GLP-1 Agonists: Saturday Sept. 21

Target Audience

This program will be of substantial interest to physicians, fellows, and other health care professionals caring for individuals with or at risk of developing endocrine conditions.

Learning Objectives

  • Demonstrate updated knowledge of the pathophysiology, diagnosis, and treatment of diabetes, obesity, cardiovascular disease, dyslipidemia, as well as adrenal, metabolic, bone, pituitary, thyroid, and reproductive endocrine disorders
  • Practice updated clinical skills for more effective diagnosis, management, and treatment of endocrine disorders and related sequelae
  • Apply updated knowledge and clinical skills in improving patient care

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Systems-based Practice
Topic Area: 
Adrenal/HPA Axis
Bone and Calciotropic Hormones
Diabetes and Glucose Metabolism
Lipid Disorders and Fatty Liver Diseases
General Endocrinology
Growth Disorders
Hormones and Cancer
Men’s Health
Neuroendocrinology and Pituitary
Obesity
Thyroid/HPT Axis
Women’s Health
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Activity summary
Available credit: 
  • 20.75 ABIM MOC
  • 20.75 AMA PRA Category 1 Credits
  • 20.75 CME Certificate of Participation
Course opens: 
09/04/2019
Course expires: 
12/31/2019
Event starts: 
09/19/2019 - 7:00am
Event ends: 
09/21/2019 - 3:30pm
Rating: 
0

 

Thursday, September 5, 2019
7:00 AMBreakfast
7:45 - 7:55 AM

Welcome and Introduction
Marc-Andre Cornier, MD

7:55 - 8:25 AM

Drug Holidays: What Patients and What Drugs?
Joy Tsai, MD

8:25 - 8:55 AM

Fracture Healing
Alan C. Dalkin, MD

8:55 - 9:25 AM

Osteoporosis in Men
Thomas J. Weber, MD

9:25 - 9:55 AM

Transplant Related Osteoporosis
Ejigayehu G. Abate, MD

9:55 - 10:10 AMQ&A/Panel Discussion
10:10 - 10:25 AMBreak
10:25 - 10:55 AM

Helping Patients Find Motivation for Lifestyle Change
Scott Kahan, MD, MPH

10:55 AM - 11:25 AM

What’s New in Obesity Treatment?
Donna H. Ryan, MD

11:25 AM- 11:55 AM          

The New Cholesterol Management Guidelines
Henry N. Ginsberg, MD

11:55 AM - 12:10 PM              Q&A/Panel Discussion
12:10 - 1:25 PMLunch
1:25 - 2:10 PM

Meet-the-Professor Breakout Sessions

Overview of Rare Bone Disease
Thomas J. Weber, MD

Osteoporosis in the Oldest Old
Ejigayehu G. Abate, MD

Pharmacotherapy for Weight Reduction
Donna H. Ryan, MD

Challenging Cases in Lipid Management
Henry N. Ginsberg, MD

When Not to Use Testosterone in Men
Bradley D. Anawalt, MD

HRT for Women
Margaret E. Wierman, MD

2:10 - 2:25 PMBreak
2:25 - 2:55 PM

Hypogonadal Cases
Bradley D. Anawalt, MD

2:55 - 3:25 PM

Testosterone Replacement Modalities: Pros, Cons, & their Correct Use
Shezad S. Basaria, MBBS

3:25 - 3:40 PMQ&A/Panel Discussion
3:40 - 3:55 PMBreak
3:55 - 4:25 PM       

PCOS Treatment
Andrea E. Dunaif, MD

4:25 - 4: 55 PM

Controversies in the Treatment of Women with Menopausal Hormones

Panelists: 
Margaret E. Wierman, MD
Cynthia A. Stuenkel, MD

4:55 - 5:10 PMQ&A/Panel Discussion
5:10 - 5:15 PMBreak
5:15 - 6:00 PM

Meet-the-Professor Breakout Sessions

Overview of Rare Bone Disease
E. Michael Lewiecki, MD

Osteoporosis in the Oldest Old
Ejigayehu G. Abate, MD

Pharmacotherapy for Weight Reduction
Donna H. Ryan, MD

Challenging Cases in Lipid Management
Henry N. Ginsberg, MD

When Not to Use Testosterone in Men
Bradley D. Anawalt, MD

HRT for Women
Margaret E. Wierman, MD

6:00 PM

Welcome Reception

 

 

Friday, September 6, 2019
7:00 AMBreakfast
7:45 - 7:50 AM

Welcome and Introduction
Marc-Andre Cornier, MD

7:50 - 8:30 AM

Diabetes on a Budget
Marie E. McDonnell, MD

8:30 - 9:00 AM

Contemporary Management of Type 1 Diabetes in Pregnancy
Denice Feig, MD, MSc

9:00 - 9:30 AM

Update on Diabetic Nephropathy 
Robert C. Stanton, MD

9:30 - 9:45 AMQ&A/Panel Discussion
9:45 - 10:00 AMBreak
10:00 - 10:30 AM

Glycemic Management after Bariatric Surgery
Mary-Elizabeth Patti, MD

10:30 - 11:00 AM             

Safety of Novel Agents in Type 2 Diabetes Management
Carol Wysham, MD

11:00 - 11:30 AM

Challenges with Technology: Difficult Pump & CGM Cases
Anders Carlson, MD

11:30 - 11:50 AMQ&A/Panel Discussion
11:50 AM - 1:10 PM     Lunch
1:10 - 1:55 PM

Meet-the-Professor Breakout Sessions

Treatment of Diabetes in the Elderly
Anders Carlson, MD

Revisiting Old Drugs for Type 2 Diabetes
Marie E. McDonnell, MD

Challenges in the Evaluation and Management of Hypoglycemia
Mary-Elizabeth Patti, MD

Pancreatic Diabetes
Melena D. Bellin, MD

Adrenal Cushing Diagnosis and Management
Lynnette K. Nieman, MD

Adrenal Incidentaloma: Challenging Cases
William F. Young, Jr., MD, MSc

1:55 - 2:05 PMBreak
2:05 - 2:35 PM

Challenges of Managing Paraganglioma & Pheochromocytoma 
Lauren Fishbein, MD, PhD

2:35 - 3:05 PM

Adrenal Questions and Answers
William F. Young, Jr., MD, MSc

3:05 - 3:35 PM                  

Diagnosis and Management of Adrenal Insufficiency
Lynnette K. Nieman, MD

3:35 - 3:55 PMQ&A/Panel Discussion
3:55 - 4:15 PMBreak
4:15 - 5:00 PM

Meet-the-Professor Breakout Sessions

Treatment of Diabetes in the Elderly
Anders Carlson, MD

Revisiting Old Drugs for Type 2 Diabetes
Marie E. McDonnell, MD

Challenges in the Evaluation and Management of Hypoglycemia
Mary-Elizabeth Patti, MD

Pancreatic Diabetes
Melena D. Bellin, MD

Adrenal Cushing Diagnosis and Management
Lynnette K. Nieman, MD

Adrenal Incidentaloma: Challenging Cases
William F. Young, Jr., MD, MSc

5:00 PMClosing

 

Saturday, September 7, 2019
7:00 AMBreakfast
7:45 - 7:55 AM

Welcome and Introduction
Marc-Andre Cornier, MD

7:55 - 8:25 AM

Cushing's Disease: Update on Treatment
Maria Fleseriu, MD

8:25 - 8:55 AM

Non-Functioning Pituitary Adenomas
Shlomo Melmed, MD

8:55 - 9:25 AM

Prolactinomas: Special Topics 
Laurence Katznelson, MD

9:25 - 9:40 AMQ&A/Panel Discussion
9:40 - 9:55 AM              Break
9:55 - 10:40 AM

Meet-the-Professor Breakout Sessions

Hypophysitis: Etiology and Management
Maria Fleseriu, MD

Diagnosis and Management of Hyponatremia
Joseph G. Verbalis, MD

Grave’s Orbitopathy
George J. Kahaly, MD, PhD

Treatment Options for Advanced Thyroid Cancer
Stephanie Fish, MD

Molecular Markers in the Workup of Thyroid Nodules
Matthew Ringel, MD

10:40 - 10:50 AMBreak
10:50 - 11:20 AM

Risk Stratification in Thyroid Cancer
Stephanie Fish, MD

11:20 - 11:50 AM

Diagnosis and Management of Graves’ Hyperthyroidism 
George J. Kahaly, MD, PhD

11:50 AM - 12:05 PMQ&A/Panel Discussion
12:05 - 1:20 PMLunch
1:20 - 2:05 PM

Meet-the-Professor Breakout Sessions

Hypophysitis: Etiology and Management
Maria Fleseriu, MD

Diagnosis and Management of Hyponatremia
Joseph G. Verbalis, MD

Grave’s Orbitopathy
George J. Kahaly, MD, PhD

Treatment Options for Advanced Thyroid Cancer
Stephanie Fish, MD

Molecular Markers in the Workup of Thyroid Nodules
Matthew Ringel, MD

2:05 - 2:10 PMBreak
2:10 - 2:40 PM

Clinical Update on Thyroid and Pregnancy 
Elizabeth N. Pearce, MD, MSc

2:40 - 3:25 PM

Unusual Thyroid Function Tests: Cases to Panelists

Panelists: 
Stephanie Fish, MD
George J. Kahaly, MD, PhD
Elizabeth N. Pearce, MD, MSc

3:25 - 3:30 PMClosing
Hyatt Regency Seattle
808 Howell Street
Seattle, WA 98101
United States
+1 (206) 973-1234

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s Clinical Endocrinology Update Steering Committee.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.


CLINICAL ENDOCRINOLOGY UPDATE STEERING COMMITTEE

The following steering committee members reported the following relevant financial relationship(s) that they or their spouse/partner have with commercial interests:

Daniel Bessesen, MD has served on the Safety Monitoring Committee for Enteromedics, Inc; and has received grant support from the National Institutes of Health. 

Sigridur Bjornsdottir, MD, PhD has served on an advisory group for Amgen; has received research support from Shire; and has been a speaker for Mylan and Shire. 

Marc-Andre Cornier, MD has received grant funding from the National Institutes of Health, the Department of Veterans Affairs, and Regeneron. 

Monica Gadelha, MD, PhD has served on an advisory board for Novartis; has served as a lecturer for Novartis, Ipsen, and Pfizer; has received an unrestricted research grant from Ipsen; has served as primary investigator of clinical trials for Novartis and Ipsen; and has been employed by Instituto Estadual do Cerebro Paulo Niemeyer. 

Whitney Goldner, MD has served as primary investigator for Eisai (phase 3 trial) and Roche; and has served as a member of the NCCN thyroid cancer guidelines panel and adrenal tumor/neuroendocrine tumor guidelines panel; and has served on the Trainee and Early Career Development Committee, Awards Committee and Thyroid Cancer Guidelines committee for American Thyroid Association.

Tim Korevaar, MD, PhD has received speaker fees from Goodlife Healthcare B.V., Berlin Chemie, and Quidel. 

Connie Baum Newman, MD has served as a member of the National Lipid Association's Graduate Medical Education Committee and American Heart Association's Clinical Lipidology Committee; has served as the past president of the American Medical Women's Association; and has served on the Food and Drug Administration's Endocrinologic and Metabolic Diseases Advisory Committee. 

Camille Powe, MD has received salary support and grant funding from the NIH National Institute of Diabetes and Digestives and Kidney Diseases (K23) and the Robert Wood Johnson Foundation's Harold Amos Faculty Development Program; has served as section editor for Current Diabetes Reports; and has participated in the NIH Clinical Research Loan Repayment Program.  

Micol Rothman, MD has served on the Professional Practice Committee of the American Society for Bone and Mineral Research.

The following faculty report no relevant financial relationships: Richard Bebb, MD; Serena Cardillo, MD


PRESENTING FACULTY

The following presenting faculty reported the following relevant financial relationship(s) that they or their spouse/partner have with commercial interests:

Bradley Anawalt, MD has served as a consultant to the United States Anti-Doping Agency; has received grant funding from the NIH; has served as a Senior Editor for Clinical Endocrinology; and has written chapters in Up-To-Date and Williams, Greenspan and DeGroot's Textbooks of Endocrinology.

Melena Bellin, MD has received research support from ViaCyte and Dexom; and has served on the Medical Advisory Board for Ariel Precision Medicine. 

Anders Carlson, MD has had his institution receive remuneration for consulting and/or clinical research from Novo Nordisk, Sanofi, Medtronic, Dexcom, Abbott, Eli Lilly, and Insulet. 

Denise Feig, MD, MSc has received speaker fees from Medtronic. 

Maria Fleseriu, MD has received scientific consulting fees from Novarits and Strongbridge; and has had her institution receive research support from Novartis, Millendo, and Strongbridge

Henry N. Ginsberg, MD has received consulting fee from Merck, Amgen, SilenceTherapeutics, Kowa, Pfizer, Janssen, and Resverlogix; and has served as an investigator for Medimmune.  

George J. Kahaly, MD, PhD has served as a consultant to Quidel USA; and has had his institution receive a research grant from Quidel. 

Mary-Elizabeth Patti, MD has served as a collaborator for NIH R44 grant funded by Xeris Pharmaceuticals; has worked as a consultant for Fractyl and Eiger Pharmaceuticals; and has received investigator-initiated research support to her institution from Xeris Pharmaceuticals and Dexcom.

Donna H. Ryan, MD has received consulting fees from Amgen, Bausch Health, Boeringer Ingelheim, Gila Therapeutics, IFA Celtic, Janssen, KVK Tech, Novo Nordisk, Phenomix, Quintiles, Real Appeal (United Health), ReDesign Health, Sanofi, and Scientific Intake; has served on the speakers bureau for Novo Nordisk; has an ownership interest in Gila Therapeutics, Phenomix, Xeno Bioscience, Epitomee, ReDesign Health and Scientific Intake; and has served on the SELECT Steering Committee for Novo Nordisk. 

Joy N. Tsai, MD has received research support from Amgen, Inc; and her spouse is employed by Amgen. 

Joseph G. Verbalis, MD has received consulting fees from Ferring Pharmaceuticals; and has received research support from Corcept Therapeutics. 

Thomas Weber, MD has served as a consultant to Ultragenyx and Pharacosmos; has received editorial support from Elsevier; has served as a primary investigator for Ultragenyx; has served as an editorial consultant to Med IQ; and has served as a permanent member to the Food and Drug Administration Endocrine and Metabolic Drug Advisory Committee. His spouse has received editorial support from Nivalis Therapeutics; has served as a primary investigator for AstraZeneca; has worked on the Study Section for the NIH National Heart, Lung and Blood Institute; and has served as a permanent member of the Food and Drug Administrations Pulmonary Allergy Drug Advisory Committee. 

Carol Wysham, MD has served as a consultant to Astra Zeneca, Abbott, Janssen, Novo Nordisk, and Sanaofi; has been in the speakers bureau for Astra Zeneca, Boehringer Ingelheim, Janssen, Novo Nordisk, and Sanofi; and has received research funding from Abbott, Novo Nordisk and Mylan. 

The following faculty report no relevant financial relationships: Ejigayehu Abate, MD; Shehzad S. Basaria, MD; Alan C. Dalkin, MD; Andrea E. Dunaif, MD; Stephanie Fish, MD; Lauren Fishbein, MD, PhD; Scott Kahan, MD, MPH; Laurence Katznelson, MD; Marie E. McDonnell, MD; Shlomo Melmed, MD; Lynnette K. Nieman, MD;  Elizabeth N. Pearce, MD, MSc; Matthew D. Ringel, MD; Robert C. Stanton, MD; Cynthia Stuenkel, MD; Lisa R. Tannock, MD; Margaret E. Wierman, MD; William F. Young, Jr, MD, MSc.

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

DISCLAIMERS
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

USE OF PROFESSIONAL JUDGMENT:
The educational content in this self-assessment test relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

DRUGS AND DOSAGES:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY AND CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This activity is supported by independent educational grants from Corcept Therapeutics, Exelixis, Lilly USA, Medtronic Diabetes, Merck & Co., Strongbridge Biopharma, and Xeris Pharmaceuticals.  

Click "Start" to complete meeting evaluation, claim CME & Maintenance of Certification (MOC) points, and print a certificate of attendance or certificate of participation

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.The Endocrine Society designates this live activity for a maximum of 20.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC):

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 20.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the responsibility of the Endocrine Society to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


Verify Your ABIM MOC Eligibility

Log in then verify your profile details in the table below to confirm ABIM MOC eligibility.  If you see your name in the table below and other information is blank or incorrect, click the Review & Edit your Profile button to update and make changes.

My NameI am Certified by the ABIMMy ABIM NumberMy Date of Birth
[current-user:profile-profile:field-first-name] [current-user:profile-profile:field-last-name]

[current-user:profile-profile:field-cert-by-abim]

[current-user:profile-profile:field-number-abim]

[current-user:profile-profile:field-dob]

 

Review & Edit your Profile>

Available Credit

  • 20.75 ABIM MOC
  • 20.75 AMA PRA Category 1 Credits
  • 20.75 CME Certificate of Participation

Accreditation Period

Course opens: 
09/04/2019
Course expires: 
12/31/2019